Clinical Trials Logo

Clinical Trial Summary

Primary Objective:

The primary objective of this study is to assess the efficacy of 18F-DCFPyL PET-CT for initial staging of prostate cancer in Veterans compared to conventional imaging (99mTc-MDP bone scan and Diagnostic CT or MRI). The primary clinical endpoint of our study is the percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT identifies M1 disease at initial staging.

Secondary Objectives:

Frequency of the change in primary treatment plan after initial staging.


Clinical Trial Description

This is a single arm Phase II clinical trial in Veterans with prostate cancer, no prior local therapy, who are at risk of having metastatic disease (PSA greater than 10, or Gleason Score greater than or equal to 4+3, or clinical stage greater than or equal to T2c). Veterans who are planned to undergo or have recently undergone conventional, routine care initial staging scans for prostate cancer (99mTc-MDP or NaF PET bone scan and diagnostic CT or MRI of pelvis) will also receive a 18F-DCFPyL PET-CT scan. The primary endpoint is the percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT scan identifies evidence of M1 disease at initial staging. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03852654
Study type Interventional
Source VA Greater Los Angeles Healthcare System
Contact Jafari Lida, M.D.
Phone 310 268 3583
Email lida.jafari@va.gov
Status Recruiting
Phase Phase 2/Phase 3
Start date July 22, 2018
Completion date June 30, 2020

See also
  Status Clinical Trial Phase
Terminated NCT04221828 - Trial of NanoPac Focal Therapy for Prostate Cancer Phase 2
Recruiting NCT02976402 - Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy Phase 1
Terminated NCT03964337 - Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer Phase 2
Not yet recruiting NCT05960149 - Use of Indocyanine Green in Robotic Prostate Surgeries Phase 4
Recruiting NCT06184464 - Prostatic Size Reduction Following of Leuprorelin Acetate
Active, not recruiting NCT03525262 - Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C) Phase 2
Completed NCT02853110 - Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer Phase 2